Early Access to Tafamidis for Patients With Transthyretin Amyloid Cardiomyopathy
Bibliographic record
Abstract
BACKGROUND: Tafamidis is a standard of care treatment for patients with transthyretin amyloid cardiomyopathy (ATTR-CM). While evidence was being assessed by regulatory authorities, a new, independent, and inclusive cohort of the phase 3 long-term extension study offered early access to tafamidis. OBJECTIVES: The purpose of this study was to present safety, mortality, and hospitalization findings for patients who received early access tafamidis. METHODS: Patients with ATTR-CM and who had not taken part in the phase 3 study were able to receive tafamidis free acid 61 mg (the dose later approved) for up to 60 months or until commercial availability in their region. Enrollment criteria were minimal. RESULTS: Among the 1,476 patients initiating tafamidis in the study between 2018 and 2023, mean (SD) age at enrollment was 76.5 (7.8) years, 88.8% were male, 85.6% had wild-type ATTR-CM, and 52.9% had NYHA functional class II symptoms (I: 14.9%, III: 30.8%, IV: 1.3%). Median exposure and follow-up were 12 (range: 0-55) and 19 (95% CI: 18.4-20.7) months, respectively. Overall, 7.6% of patients reported treatment-related adverse events, with 0.6% considered serious and 0.6% leading to study discontinuation. No new safety signals were identified. In Kaplan-Meier analyses, all-cause and cardiovascular (CV)-related mortality occurred in 23.4% and 13.8% of patients over the study period. Furthermore, 43.3% and 26.5% of patients had all-cause and CV-related hospitalizations. The total annual CV-related hospitalization rate was 0.26. CONCLUSIONS: In an inclusive patient cohort receiving early access to tafamidis, safety findings were consistent with those reported from other trials and real-world studies. (Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy; NCT02791230).
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".